Loading page
Recommended Tab
FDA approvals, label changes and boxed warning updates for hormone therapy and non-hormonal menopause drugs, guideline changes from major societies, generic launches and price changes, insurer and Medicare formulary changes, telehealth menopause clinic actions, workplace menopause policy adoptions, and major study results with clinical implications, with the drug or guideline first.
A boxed warning removal that changes a prescribing conversation, a generic that cuts a $200 monthly cost to $30, or a formulary change before a refill each matters more than the fee.
The objective your Tab starts with. You can edit every line of it once the Tab is yours.
FDA approvals, label changes and boxed warning updates for hormone therapy and non-hormonal menopause drugs, guideline changes from major societies, generic launches and price changes, insurer and Medicare formulary changes, telehealth menopause clinic actions, workplace menopause policy adoptions, and major study results with clinical implications, with the drug or guideline first.
Track menopause care for US women. Report only confirmed, source-backed items from the last 7 days: FDA approvals, label changes and boxed warning decisions for hormone therapy including estradiol, progesterone and vaginal estrogen products and non-hormonal drugs including fezolinetant and elinzanetant; guideline updates from The Menopause Society, ACOG, Endocrine Society and USPSTF; generic launches and price changes; Medicare Part D and major insurer formulary and prior authorization changes; FTC, FDA or state actions involving telehealth menopause clinics and compounded hormone products; workplace menopause policy adoptions at large employers; and peer-reviewed study results in JAMA, NEJM, Lancet or Menopause with a clear clinical implication. Prefer FDA, society, insurer, journal and company sources; ignore supplement and influencer claims. Put the drug or guideline first in the title. Use high severity for a boxed warning change, a guideline reversal, or a formulary change affecting a top-10 menopause product. Return no more than 6 findings. Push each as a finding with a title, a two-sentence summary, sections for what changed, who it applies to, what to discuss with a clinician, and the source link. Note that findings are informational and not medical advice. If nothing qualifies, push nothing and submit the run receipt.
Someone else wants the same subject? They start their own Tab from this idea. Ideas are shared; Tabs are not.
Start this Tab